Using PD-1 antibody and GEMOX for treating perihilar cholangiocarcinoma after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label, single-center, non-randomized, single-arm exploratory study aims to evaluate the efficacy and safety of combining PD-1 antibody with GEMOX chemotherapy as postoperative adjuvant therapy for patients with perihilar cholangiocarcinoma who have positively metastatic lymph nodes. The study addresses the urgent need for effective adjuvant treatments for these patients, as current survival rates are significantly lower for those with lymph node metastasis. Participants will receive the treatment after radical surgical resection, and their outcomes will be monitored to assess the potential benefits of this combined approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The patient must sign an informed consent form;
2. Age 18-75 years old, both male and female;
3. ECOG performance status score (PS score) 0 or 1 point;
4. Child-Pugh score A period;
5. Perihepatic cholangiocarcinoma with negative margins and positively metastatic lymph nodes confirmed by histopathology. Abdominal positively metastatic lymph nodes region is not limited. The 16 groups of microscopically positively metastatic lymph nodes can be included.
6. Have not received any systemic treatment within 6 months;
7. The functional indicators of important organs meet the following requirements (1)Neutrophils≥1.5\*109/L; platelets≥100\*109/L; hemoglobin≥9g/dl; serum albumin≥3g/dl; (2)Thyroid-stimulating hormone (TSH) ≤ 2 times the upper limit of normal, and T3 and T4 are in the normal range; (3)Bilirubin ≤ 1.5 times the upper limit of normal; ALT and AST ≤ 3 times the upper limit of normal; (4)Serum creatinine ≤ 1.5 times the upper limit of normal, and creatinine clearance ≥ 60ml/min (calculated by Cockcroft-Gault formula); 8. The subject has at least 1 measurable lesion (according to RECIST1.1);
8. For women who are not breastfeeding or pregnant, use contraception during treatment or 12 months after the end of treatment.

Exclusion Criteria:

1. Unresectable PHC patients or postoperative diagnosis of PHC recurrence and metastasis ;
2. Past or simultaneous suffering from other malignant tumors, except for fully treated non-melanoma skin cancer, cervical carcinoma in situ, and thyroid papillary carcinoma;
3. Have used gemcitabine-based chemotherapy or have used PD-1 monoclonal antibody or PD-L1 monoclonal antibody treatment within 6 months;
4. Severe cardiopulmonary and renal dysfunction;
5. Hypertension that is difficult to control with drugs (systolic blood pressure (BP) ≥140 mmHg and/or diastolic blood pressure ≥90mmHg) (based on the average of ≥3 BP readings obtained by ≥2 measurements);
6. Abnormal coagulation function (PT\>14s), have bleeding tendency or are receiving thrombolysis or anticoagulation therapy;
7. After antiviral treatment, HBV DNA\>2000 copies/ml, HCV RNA\>1000;
8. A history of esophageal and gastric varices, significant clinically significant bleeding symptoms or a clear tendency to appear within 3 months before enrollment;
9. Active infections requiring systemic treatment; patients with active tuberculosis infection within 1 year before enrollment; a history of active tuberculosis infection more than 1 year before enrollment, and no formal anti-tuberculosis treatment or tuberculosis Still in the active period;
10. Human immunodeficiency virus (HIV, HIV1/2 antibody) positive;
11. A history of psychotropic drug abuse, alcohol or drug abuse;
12. Known to have a history of severe allergies to any monoclonal antibodies, platinum drugs, or gemcitabine;
13. Other factors judged by the investigator may affect the safety of the subjects or the compliance of the trial. Such as serious diseases (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors.

Where it's running

• Sun Yat-sen Memorial Hospital, Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Chao Liu, PhD — Department of Biliary and Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
• Study coordinator: Rui Zhang, PhD
• Email: zhangr95@mail.sysu.edu.cn
• Phone: 020-34078840

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Preoperative Lymph Node Assessment in Cholangiocarcinoma using Endoscopic Ultrasound

  This study tests how well preoperative endoscopic ultrasound (EUS) finds lymph node metastases in adults with presumed resectable or certain unresectable cholangiocarcinomas to see if surgery should proceed.

  Recruiting Erasmus Medical Center · Rotterdam, South Holland and 5 other locations · NCT07161869

• Liver transplantation for patients with advanced bile duct cancer

  This study is testing if liver transplantation can help patients with advanced bile duct cancer who have controlled their disease with treatment.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan, Michigan · NCT06986486

• Neoadjuvant gemcitabine and cisplatin with perioperative pembrolizumab vs upfront surgery for cancers of the bile ducts

  This trial tests whether giving chemotherapy with pembrolizumab before surgery helps people with resectable or borderline resectable extrahepatic cholangiocarcinoma see if they have better outcomes than going straight to surgery.

  Recruiting Phase 2/3 Amsterdam UMC, location VUmc · Amsterdam · NCT06923475

• Robot-assisted surgery for perihilar cholangiocarcinoma

  This study is testing if robot-assisted surgery can help patients with perihilar cholangiocarcinoma remove their tumors safely and recover better than with traditional surgery.

  Recruiting Azienda Ospedaliera di Padova · Padova · NCT06720883

• Liver transplantation for patients with unresectable perihilar cholangiocarcinoma

  This study is testing if liver transplantation can help people with a specific type of cancer that can't be surgically removed feel better and live longer after they’ve had standard chemotherapy.

  Recruiting Azienda Sanitaria Ospedaliera · Padova, PADOVA · NCT06125769

• Using radiofrequency ablation to treat bile duct cancer before stent placement

  This study is testing if using a special heat treatment before placing a stent can help people with bile duct cancer feel better and keep their stents working longer.

  Recruiting Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT05546372

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.